Repatha (140 mg/ml) Injection

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Repatha (140 mg/ml) Injection contains evolocumab, a PCSK9 inhibitor. It is prescribed for high cholesterol and atherosclerosis, working alongside other cholesterol-lowering medicines and dietary measures to lower LDL (“bad”) cholesterol and reduce the risk of heart disease or stroke.

Active ingredient
Evolocumab
Strength
140 mg/ml
Dosage form
Solution for injection (pre-filled)
Therapeutic class
PCSK9 inhibitor (lipid-lowering)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with evolocumab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Management of high cholesterol (hyperlipidaemia), used together with other lipid-lowering therapy
  • Management of atherosclerosis, to help reduce plaque build-up in blood vessel walls
  • Described as helping to lower the risk of heart disease and stroke as part of a broader treatment plan
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Given as a subcutaneous injection by a trained healthcare professional, or self-administered after training, per prescribing information
  • Dose and dosing interval are set by the prescriber; the course should not be stopped early, as cholesterol levels may rise again
  • Used alongside diet, exercise, weight management, and other prescribed cholesterol medicines

Described Side Effects

Commonly described side effects include:

  • Injection-site reactions (pain, swelling, redness)
  • Nasopharyngitis or influenza-like symptoms
  • Upper respiratory tract infection
  • Back pain

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Not indicated for use during pregnancy or breastfeeding, per manufacturer guidance
  • Diabetic patients should monitor blood sugar levels regularly while on treatment
  • Full medical history and current medicines should be shared with the prescriber
  • Regular cholesterol monitoring and lifestyle measures are advised

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, Repatha contains evolocumab, a PCSK9 inhibitor used with other lipid-lowering therapy for high cholesterol and atherosclerosis, to help reduce cardiovascular risk. SDO Pharma has not independently verified these claims.

It is given as a subcutaneous injection by a healthcare professional, or self-administered after training, at the interval set by the prescriber.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services